The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns

Ann Dermatol Venereol. 2024 Mar;151(1):103243. doi: 10.1016/j.annder.2023.103243. Epub 2024 Feb 6.
No abstract available

Keywords: BRAF mutation; Ipilimumab; Metastatic melanoma; Nivolumab; Reimbursement.

Publication types

  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • France
  • Humans
  • Ipilimumab / therapeutic use
  • Melanoma* / drug therapy
  • Melanoma* / genetics
  • Nivolumab / therapeutic use
  • Proto-Oncogene Proteins B-raf / genetics
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / genetics

Substances

  • Nivolumab
  • Ipilimumab
  • Proto-Oncogene Proteins B-raf
  • BRAF protein, human